Nexell to Ax Dozens, Hand Off Sales Rights
Struggling Nexell Therapeutics Inc. said Tuesday it will fire two-thirds of its work force and transfer rights to its cell-processing products to its biggest shareholder, Baxter International Inc.
The Irvine developer of cell therapies to treat cancer and other diseases, said Baxter’s health-care unit will obtain worldwide sales, marketing and distribution rights for Nexell’s flagship Isolex magnetic cell-selection system, cell culture and storage containers and other products.
Terms of the deal were not announced. Nexell said it would take a one-time charge later this year, partly for severance pay for about 66 of its 100 workers.
Baxter, based in Deerfield, Ill., owns nearly 12 million shares, or about 38%, of Nexell, according to a document recently filed with the Securities and Exchange Commission.
Nexell stock dropped 35 cents Tuesday to close at $2.50 a share in Nasdaq trading. The firm’s shares have lost 85% of their value in the last 52 weeks.
Baxter closed at $49.31, down 7 cents a share, on the New York Stock Exchange.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
